Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity (Nasdaq: CELC) will release first quarter 2026 financial results after market close on Thursday, May 14, 2026.

Rhea-AI Summary

Celcuity (Nasdaq: CELC) will release first quarter 2026 financial results after market close on Thursday, May 14, 2026. Management will host a live webcast and teleconference the same day at 4:30 p.m. Eastern Time to review results and provide a corporate update. A webcast replay will be available on the company website.

Argus May 7 session

-6.26% close to close Open Argus

Details

News Market Reaction – CELC

In the May 7 session, CELC declined 6.26%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.3% in the session following this news. A negative reaction despite this being a r...

Analysis

The stock moved -6.3% in the session following this news. A negative reaction despite this being a routine Q1 2026 scheduling update would fit a pattern where timing notices themselves carry limited fundamental information. Past event-driven spikes, such as the 15.38% move on Phase 3 data, contrasted with mild shifts around prior earnings-scheduling releases. The presence of an effective S-3ASR for up to $400,000,000 in potential issuance may also color risk perceptions.

Key Figures

Q1 2026 results date: May 14, 2026 Earnings call time: 4:30 p.m. Eastern Time Domestic dial-in: 1-800-717-1738 +5 more

Q1 2026 results date

May 14, 2026

First quarter 2026 financial results release after market close

Earnings call time

4:30 p.m. Eastern Time

Webcast/teleconference to discuss Q1 2026 results

Domestic dial-in

1-800-717-1738

U.S. participants for Q1 2026 teleconference

International dial-in

1-646-307-1865

Non-U.S. participants for Q1 2026 teleconference

ATM capacity

$400,000,000

Automatic shelf registration with Jefferies at-the-market program

Current price

$139.415

Pre-announcement price, down 1.59% over prior 24 hours

52-week range

$9.51–$151.02

Shares up 1365.98% vs low and 7.68% below high

Market capitalization

$6,848,823,481

Equity value before Q1 2026 earnings timing announcement

Previous Conferences,earnings Reports

5 past events · Latest: Mar 18

Same Type 5 events

1. Mar 18

   Earnings scheduling

   24h Move

   -1.4%

   Announced Q4 and full-year 2025 results date and webcast logistics.

2. Nov 05

   Earnings scheduling

   24h Move

   +2.2%

   Set Q3 2025 results release date and post-close webcast details.

3. Aug 07

   Earnings scheduling

   24h Move

   +0.1%

   Scheduled Q2 2025 financial results and 4:30 p.m. ET conference call.

4. May 07

   Earnings scheduling

   24h Move

   +0.6%

   Announced Q1 2025 results timing and investor call access numbers.

5. Mar 24

   Earnings scheduling

   24h Move

   +3.2%

   Outlined Q4 and full-year 2024 results date and webcast/call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1760785&tp_key=2f73ec65ba. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer (“ABC”), has reported detailed results for the PIK3CA wild-type cohort and topline results for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with endocrine resistant HR+/HER2- ABC, is ongoing. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Celcuity (CELC) release its first quarter 2026 financial results?

Celcuity will release Q1 2026 results after the market closes on Thursday, May 14, 2026. According to Celcuity, management will discuss results the same day during a 4:30 p.m. ET webcast and teleconference that provides a corporate update.

How can investors join the Celcuity (CELC) Q1 2026 webcast and teleconference?

Investors can join the live webcast via the provided web link or dial into the teleconference numbers. According to Celcuity, the webcast URL and dial-in details are published for the May 14, 2026 event for real-time participation.

What are the dial-in numbers for domestic and international callers for the CELC May 14, 2026 call?

Domestic callers should dial 1-800-717-1738; international callers should dial 1-646-307-1865. According to Celcuity, both numbers will connect participants to the live teleconference accompanying the Q1 2026 results presentation.

Will a replay of the Celcuity (CELC) Q1 2026 webcast be available after the live event?

Yes; a replay will be available on the Celcuity website following the live webcast. According to Celcuity, the webcast replay will be posted after the May 14, 2026 presentation for on-demand viewing by investors.

What will Celcuity (CELC) management discuss during the May 14, 2026 webcast and conference call?

Management will discuss the company’s first quarter 2026 financial results and provide a corporate update during the webcast. According to Celcuity, the call is intended to review results and offer context about ongoing clinical and corporate developments.

Where can investors access the Celcuity (CELC) live webcast link for the May 14, 2026 event?

The live webcast can be accessed via the company’s hosted webcast URL provided for the event. According to Celcuity, the specific webcast link is published for the May 14, 2026 presentation and a replay will be posted afterwards.